Overview

Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917

Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
This study will compare glucose lowering with CS-917 compared to placebo after 3 months of treatment
Phase:
Phase 2
Details
Lead Sponsor:
Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.
Treatments:
Metformin
Pioglitazone